Welcome to our dedicated page for Vtv Therapeutics news (Ticker: VTVT), a resource for investors and traders seeking the latest updates and insights on Vtv Therapeutics stock.
vTv Therapeutics Inc. reports developments as a late-stage biopharmaceutical company focused on oral, small-molecule drug candidates for diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a liver-selective glucokinase activator being investigated as an oral adjunctive therapy to insulin for type 1 diabetes. Company updates also reference development work and partnerships across additional chronic-disease candidates, including the PDE4 inhibitor HPP737.
Recurring announcements include clinical and regulatory updates for cadisegliatin, financial results and corporate updates, license and collaboration activity, investor-conference participation, and Nasdaq inducement grants under equity compensation plans. News about vTv often connects pipeline progress with funding arrangements, intellectual property, and business-development agreements that support its drug-development strategy.
On June 1, 2022, vTv Therapeutics (Nasdaq: VTVT) announced a $25 million investment from G42 Investments, acquiring 10,386,274 shares at $2.407 each. The investment partly funds Phase 3 clinical trials for TTP399, a glucokinase activator for type 1 diabetes. Additional shares worth $30 million may be issued if the FDA approves TTP399. This collaboration signifies a strategic partnership aimed at accelerating drug development and commercialization, leveraging G42's resources and expertise. TTP399 has shown promising results, including significant reductions in hypoglycemic episodes.
vTv Therapeutics Inc. (Nasdaq: VTVT) reported Q1 2022 financial results, highlighting a revenue of $2 million, primarily due to increased transaction prices from licensing agreements. The company continues to focus on its lead program TTP399 for type 1 diabetes while pausing development on HPP737. As of March 31, 2022, cash reserves were $12.1 million. Net loss before non-controlling interest was $9.4 million, slightly down from $9.5 million in the previous quarter. The diluted net loss per share improved to ($0.10).
vTv Therapeutics Inc. (Nasdaq: VTVT) reported its financial results for Q4 and the full year ended December 31, 2021. The company experienced a net loss of $9.5 million for Q4, increasing from $1.5 million in Q3 2021. Revenue for Q4 was negligible at $9 compared to $3 million in Q3. R&D expenses rose to $5.4 million, while G&A expenses surged to $5.7 million. The company has appointed Richard Nelson as Acting CEO and is focusing on developing TTP399 for type 1 diabetes, with plans for pivotal trials commencing in Q3 2022. Cash decreased to $13.4 million by year-end.
vTv Therapeutics Inc. (Nasdaq: VTVT) announced the appointment of Rich Nelson as Acting CEO following the resignation of Deepa Prasad. Nelson, a board member since 2020, brings extensive experience in corporate development and mergers. Prasad will remain as a Strategic Advisor for six months. The company is focused on advancing its lead drug, TTP399, which received FDA Breakthrough Therapy Designation after showing a 40% reduction in hypoglycemic episodes in its Phase 2 study. vTv aims to launch pivotal trials for TTP399 in 2022.
vTv Therapeutics (Nasdaq: VTVT) has updated its corporate presentation on TTP399, a novel treatment aimed at reducing hypoglycemic episodes in diabetes patients. The drug may act as an oral adjunctive therapy in the $16B insulin market. Nearly 600 patients have been tested with no diabetic ketoacidosis reported. vTv holds worldwide rights for TTP399 and plans global pivotal trials in 2022 while seeking non-dilutive capital through licensing outside North America and Europe. Additionally, the company explores licensing for HPP737 and other assets.
vTv Therapeutics Inc. (Nasdaq: VTVT) announced a 65% workforce reduction to prioritize its lead program, TTP399, for type 1 diabetes, as it prepares for Phase 3 pivotal trials. TTP399 demonstrated a ~40% reduction in hypoglycemic episodes compared to placebo in Phase 2 studies and has received Breakthrough Therapy Designation from the FDA. The company also suspended development on HPP737, a psoriasis treatment, while supporting partnered programs. vTv aims to focus on improving the quality of life for diabetes patients with TTP399.
vTv Therapeutics Inc. (Nasdaq: VTVT) reported third-quarter 2021 financial results, highlighting a cash position of $19.6 million, up from $10.8 million in Q2 2021. The company generated $3.0 million in revenue, largely from milestones achieved with partners. Net loss attributable to shareholders was $1.09 million, or $(0.02) per share, compared to $(0.01) in Q2 2021. The firm is refocusing on TTP399 for type 1 diabetes, having received FDA Breakthrough Therapy Designation. Upcoming pivotal studies for TTP399 are planned for H1 2022, with cost reduction measures being evaluated.
vTv Therapeutics Inc. (Nasdaq: VTVT) announces the appointment of Deepa Prasad as President and CEO, effective immediately, following the retirement of Stephen L. Holcombe. Under her leadership, the company plans to launch phase 3 studies for TTP399, an oral therapy for type 1 diabetes, which received Breakthrough Therapy Designation from the FDA. Recent phase 2 results showed significant HbA1c improvement and reduced hypoglycemia risk. Prasad brings over 20 years of healthcare experience, having previously led investments in prominent firms.
vTv Therapeutics announced positive results from a mechanistic study of TTP399, a treatment for type 1 diabetes (T1D), indicating it does not increase blood ketone levels during insulin withdrawal, minimizing the risk of ketoacidosis. Patients on TTP399 experienced improved fasting plasma glucose and fewer hypoglycemic events compared to placebo, with no incidents of hypoglycemia reported. The study, involving 23 participants, met its primary endpoint and sets the stage for a Phase 3 program expected to commence in early 2022.
vTv Therapeutics announced positive results from a multiple ascending dose study of HPP737, an orally administered PDE4 inhibitor, in healthy adults. The study showed a favorable safety profile without dose limiting gastrointestinal side effects. With a successful pre-IND meeting with the FDA, vTv plans to submit an IND application for a Phase 2 trial in moderate to severe psoriasis later this year, with the study set to begin in early 2022. These results suggest potential for HPP737 as a safer alternative for treating psoriasis.